Recruiting

VISIONVV-14295 for Geographic Atrophy in Age-related Macular Degeneration

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

VV-14295

Genetic
Who is being recruted

From 55 to 80 Years
+20 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1 & 2
Interventional
Study Start: May 2025
See protocol details

Summary

Principal SponsorKriya Therapeutics, Inc.
Study ContactVP, Medical Affairs
Last updated: December 13, 2025
Sourced from a government-validated database.Claim as a partner

Study start date: May 28, 2025

Actual date on which the first participant was enrolled.

This study aims to assess the safety and effectiveness of a new treatment called KRIYA-825 (VV-14295) for individuals with a specific eye condition known as geographic atrophy (GA) caused by age-related macular degeneration (AMD). Geographic atrophy is a serious condition leading to vision loss in older adults, and there is a significant need for treatments that can slow down or stop its progression. By testing this treatment, the study hopes to find a potential way to reduce the growth of GA lesions, which are damaged areas in the eye that worsen over time. Participants in the study will receive the KRIYA-825 treatment through a method called suprachoroidal injection, using a special device called the Everads Injector. This way of delivering the treatment targets the affected areas in the eye more directly. The study will focus on observing the safety and tolerability of the treatment, which means checking for any side effects or discomforts, and evaluating its effectiveness in slowing down the growth of GA lesions. While the study does not list specific outcomes, it is an important step in finding a treatment for those suffering from this vision-threatening condition.

Official TitleA Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally With the Everads Injector In AdultS With GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study) 
NCT06765980
Principal SponsorKriya Therapeutics, Inc.
Study ContactVP, Medical Affairs
Last updated: December 13, 2025
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

62 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 55 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

7 inclusion criteria required to participate
Participant must be between 55 to 80 years of age (inclusive), at the time of signing the informed consent form.
Body mass index (BMI) of 19 to 34 kg/m2 (inclusive).
Must agree to use reliable contraception for at least 12 months after administration of VV-14295. A female participant is eligible to participate if she is not pregnant and not breastfeeding.
The GA lesion must meet certain criteria as assessed by a central reading center's assessment of imaging at Screening.
Show More Criteria
13 exclusion criteria prevent from participating
Any ocular disease or condition that is not GA secondary to AMD: Macular atrophy secondary to a condition other than AMD; Exudative AMD diagnosis or any history of or active macular neovascularization (in study eye or fellow eye) and/or retinal angiomatous proliferation associated with AMD or any other cause; Presence of an active ocular disease that in the opinion of the Investigator compromises or confounds visual function; Active ocular or periocular infection or active uncontrolled intraocular inflammation within 3 months of Screening; History of vitrectomy, retinal detachment, or corneal transplant in the study eye; Active/history of uveitis.
Any ocular condition that prevents adequate imaging.
Medical, cognitive or psychiatric conditions that, in the opinion of the Investigator, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or could increase the risk to the participant by participating in the study or confound the outcome of the study.
Hospitalization within 1 year prior to Screening that, in the opinion of the Investigator, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or could increase the risk to the participant by participating in the study or confound the outcome of the study.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

4 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
A single high dose of VV-14295 will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

Group II

Experimental
A single low dose of VV-14295 will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

Group III

Experimental
A single dose of VV-14295 determined from Part 1a will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

Group IV

Experimental
A single dose of VV-14295 determined from Part 1a will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Recruiting

Kriya Clinical Study Site

Ottawa, CanadaSee the location
Recruiting

Kriya Clinical Study Site

Christchurch, New Zealand
Recruiting
2 Study Centers